The business community is being challenged to support life changing cancer research by entering teams in Australia’s biggest cycling fundraising ride.
The MACA Cancer200 is popular with major corporate organisations looking to make a difference and raise funds for medical researchers aiming to make discoveries in their laboratories that will lead to better treatment and higher survival rates.
Harry Perkins Institute of Medical Research Director Professor Peter Leedman says the MACA Cancer200 is a ride that offers a fabulous team building experience for corporate teams and individuals.
“Our ride is a marvellous opportunity for leaders in the business community to get out of their comfort zone and challenge themselves for a great cause,” Professor Leedman said.
“I do the ride each year and it’s wonderful to see the business community out in numbers and making such a positive difference to the future of cancer treatment and research.
“We have fabulous feedback about the difference this has made to team spirit in the workplace and the longer term benefits the ride has on collaboration and team building.
“It’s a ride not a race and now is the time to get the bike out and start cycling, ahead of our event in October.
“We have people of all ages and abilities doing the ride; the emphasis is on fun and fundraising.”
The MACA Cancer200 from Perth to Mandurah and back over two days in October will start and finish at Perth’s iconic new Optus Stadium, with all funds raised to fast track cancer research that will transform treatment options and survival rates for patients.
The ride on October 26-27 aims to raise $4 million to allow ground breaking laboratory research to go ahead at the Harry Perkins Institute of Medical Research.
Cycling fan and cancer survivor Steve Williams is entering his seventh race this year.
“I’ve seen the impact that the big corporate teams can have on an event like this,” Steve said.
“They’re out of their workplaces and into a ride and they are so positive and passionate about making a difference and doing something that leaves a genuine legacy.
“I know first-hand that the work in the labs to develop new treatments, new drugs and new approaches is just so important for the future.
“I’d encourage any corporate team looking for a challenge to register and test themselves in this amazing experience.”